Clinical Trials Sponsored by Parker Jewish Institute
Total 1990 results
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI)Completed
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI)TerminatedDuctal Carcinoma in Situ | Invasive Breast Cancer (Stage I-III) | Lobular Carcinoma in Situ | Lobular Carcinoma | Fatigue Related to Cancer TreatmentUnited States
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI)Completed
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI)Completed
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI)CompletedInflammatory Breast CarcinomaUnited States
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI)CompletedLymphoma | Myelodysplastic Syndromes | Leukemia | Myeloma | Graft Versus Host DiseaseUnited States
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI)CompletedGraft Versus Host DiseaseUnited States
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI)CompletedSarcoma | Kidney Cancer | Testicular Germ Cell Tumor | Head and Neck Cancer | Ovarian Cancer | Lung Cancer | Brain and Central Nervous System Tumors | Unspecified Adult Solid Tumor, Protocol Specific | Bladder Cancer | Extragonadal Germ Cell Tumor | Carcinoma of Unknown PrimaryUnited States
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI)CompletedHead and Neck CancerUnited States
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI)Completed
-
Dana-Farber Cancer InstituteCompletedPain | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI)CompletedQuality of Life | Palliative Care | Outcome Assessment | Pediatric NeoplasmUnited States
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI)CompletedSarcoma | Brain and Central Nervous System Tumors | Gastrointestinal Stromal TumorUnited States
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI)UnknownMelanoma (Skin)United States
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI)UnknownHead and Neck CancerUnited States
-
Dana-Farber Cancer InstituteImmunityBio, Inc.Not yet recruitingOvarian Cancer | Platinum-resistant Ovarian Cancer | Ovarian Carcinoma | Recurrent Ovary Cancer | Ovarian Carcinoma, RecurrentUnited States
-
Dana-Farber Cancer InstituteNest GenomicsRecruitingGenetic Predisposition to Disease | Genetic PredispositionUnited States
-
Dana-Farber Cancer InstituteCelldex TherapeuticsRecruitingMelanoma | Metastatic MelanomaUnited States
-
Dana-Farber Cancer InstituteGenentech, Inc.RecruitingBreast Cancer | HER2-positive Breast Cancer | Hormone Receptor Positive Breast Cancer | Invasive Carcinoma of the Breast | Node Negative Breast Cancer | Micrometastasis Breast CancerUnited States
-
Dana-Farber Cancer InstituteIncyte CorporationActive, not recruitingInflammatory Breast Cancer (IBC)United States
-
Dana-Farber Cancer InstituteRoche-GenentechActive, not recruitingGraft vs. Host DiseaseUnited States
-
Dana-Farber Cancer InstituteHiberCell, Inc.CompletedRelapsed/Refractory Indolent B Cell Non-Hodgkin LymphomasUnited States
-
Dana-Farber Cancer InstituteGenentech, Inc.Active, not recruitingAdvanced Non-Clear Cell Kidney CancerUnited States
-
Dana-Farber Cancer InstituteTesaro, Inc.Active, not recruiting
-
Dana-Farber Cancer InstituteEisai Inc.Active, not recruitingInflammatory Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of BreastUnited States
-
Dana-Farber Cancer InstituteAmbry GeneticsCompletedBreast Cancer | Pancreatic Cancer | Ovarian Cancer | Metastatic Prostate CancerUnited States
-
Dana-Farber Cancer InstituteGenentech, Inc.Active, not recruitingChronic Lymphocytic LeukemiaUnited States
-
Dana-Farber Cancer InstituteTakeda; CelgeneActive, not recruitingSmoldering Multiple MyelomaUnited States
-
Dana-Farber Cancer InstituteEntrinsic HealthCompletedMultiple Myeloma | Non-Hodgkin's LymphomaUnited States
-
Dana-Farber Cancer InstituteJanssen, LPCompletedWaldenström MacroglobulinemiaUnited States
-
Dana-Farber Cancer InstituteMedivation, Inc.CompletedMetastatic Castration-resistant Prostate CancerUnited States
-
Stanford UniversityBascom Palmer Eye InstituteCompletedMacular Degeneration | Retinal DrusenUnited States
-
Dana-Farber Cancer InstituteGenentech, Inc.TerminatedALK-positive Non-small Cell Lung Cancer (NSCLC) | RET-positive Non-small Cell Lung Cancer (NSCLC) | RET-positive Thyroid CancerUnited States
-
Dana-Farber Cancer InstituteBayer; PfizerCompletedGastrointestinal Stromal TumorUnited States
-
Dana-Farber Cancer InstituteIncyte CorporationCompletedMetastatic Breast Cancer | Recurrent Breast CancerUnited States
-
Dana-Farber Cancer InstituteNovartis; AstraZenecaCompleted
-
Dana-Farber Cancer InstituteJanssen PharmaceuticalsTerminatedProstate CancerUnited States
-
Dana-Farber Cancer InstituteCelgene CorporationTerminatedOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal CarcinomaUnited States
-
AEterna ZentarisDana-Farber Cancer InstituteCompletedRenal Cell CarcinomaUnited States
-
Fate TherapeuticsDana-Farber Cancer InstituteCompletedHematologic Malignancies | Allogeneic Stem Cell TransplantationUnited States
-
Baker Heart and Diabetes InstituteNot yet recruitingHeart Failure | Cognitive Impairment | Dementia | Cognitive Change | Cognitive Decline | Left Ventricular Dysfunction
-
Baker Heart and Diabetes InstituteCompleted
-
Baker Heart and Diabetes InstituteTerminated
-
Baker Heart and Diabetes InstituteTerminatedPeripheral Arterial Disease | Intermittent ClaudicationAustralia
-
Northwell HealthNational Institute of Mental Health (NIMH); Long Island Jewish Medical CenterCompleted
-
Dana-Farber Cancer InstituteMedWaves, IncNot yet recruitingLung Cancer | Lung Cancer Stage I | Lung Cancer Stage II | Stage I Lung Cancer | Stage I - II Primary Lung Cancer | Stage II Lung CancerUnited States
-
Dana-Farber Cancer InstituteGenentech, Inc.Recruiting
-
Dana-Farber Cancer InstituteGenentech, Inc.RecruitingSalivary Gland Cancer | HER2 Gene MutationUnited States
-
Dana-Farber Cancer InstituteGenentech, Inc.RecruitingRichter SyndromeUnited States
-
Dana-Farber Cancer InstituteJanssen PharmaceuticaActive, not recruitingProstate CancerUnited States